Gene Therapy Focus AveXis is a leading gene therapy company under Novartis with a strong CNS disease program, offering opportunities to collaborate on vector optimization, delivery mechanisms, and regulatory strategy for central nervous system genetic disorders.

Expanding Platform The company has established AAV9 as a foundational vector and is building a best-in-class pipeline, suggesting potential partnerships or licensing discussions for novel genetic diseases or expansion into Rett syndrome and ALS genetic forms.

Strategic Partnerships Recent Novartis-led initiatives and collaborations indicate openness to external collaborations; a targeted outreach to co-develop or access complementary technologies (delivery, manufacturing, analytics) could accelerate joint programs.

Scale & Capabilities AveXis operates with a sizeable workforce and global backing; opportunities exist to provide specialized services (manufacturing support, process development, quality systems, data analytics) to support scale-up of gene therapies.

Commercial & Regulatory Readiness With FDA approval for SMA and ongoing regulatory pathways for genetic therapies, there is potential to engage in market access, real-world evidence generation, and health economics collaborations to support payer readiness and broad adoption.